Micro Medical Solutions Obtains CE Mark Approval for MicroStent Device

 

February 13, 2017—Micro Medical Solutions announced that it has obtained CE Mark approval for its MicroStent device. According to the company, MicroStent is a vascular stent that is designed to reduce below-the-knee amputations due to critical limb ischemia (CLI) resulting from peripheral artery disease.

“The MicroStent is the centerpiece of an integrated delivery platform that will help fill an unmet need in the interventional community,” commented Jihad Mustapha, MD, in the company’s announcement. He continued, “Amputation prevention in this CLI patient population is an ongoing fight, and we welcome new tools that have such promise to make a difference.” Dr. Mustapha is a board-certified interventional cardiologist specializing in minimally invasive, nonsurgical therapy for heart and peripheral vascular disease.

The MicroStent device is the latest addition to Micro Medical Solutions’ Micro Vascular Integrated Platform (mVIP), which also includes the MicroBalloon and MicroGuide. According to the company, these technologies together are designed to provide optimal treatment of CLI lesions below the knee, reducing the risk of amputation.

The MicroBalloon and MicroGuide have previously received CE Mark and 510(k) clearances. All three devices in the mVIP device line are not available for use in the United States.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.